Laboratory pipette dispensing liquid into test tubes

Use Cases

Where Biomarkers Change Outcomes

Objective, blood-based proof of injury that drives higher settlements and strengthens every phase of a case.

Request a Briefing Legal Applications

$0M+

Highest Documented Settlement

Award Increase with Biomarkers

No Cap

Cap on TX PI Non-Economic Damages

How Biomarkers Drive Higher Awards

Four Pathways to Greater Compensation

Objective Evidence

Biomarkers confirm neuronal damage even when CT scans are negative, countering defense arguments that symptoms are subjective.

Court Credibility

Quantifiable lab data makes claims more compelling to juries and supports gross negligence and punitive damage arguments.

Higher Economic Damages

Confirmed TBI justifies extensive rehabilitation, long-term care, and lost earnings claims across all severity levels.

Non-Economic Damages

Validates pain and suffering, emotional distress, and post-concussion syndrome with uncapped potential in Texas PI cases.

Recent Texas TBI Settlements

Real Cases, Real Impact

$4M

Semi-Truck Accident

2024

$1.2M

Car Crash

2025

$900K

Construction Site

2025

$252K–$850K

Slip and Fall

2024

The Biomarker Advantage

Award Uplift by Severity

Mild TBI

Concussion

Without Biomarkers

$50K–$150K

With Biomarkers

$100K–$500K

Up to 3.3x

Moderate TBI

Without Biomarkers

$150K–$500K

With Biomarkers

$500K–$2M

Up to 4x

Severe TBI

Without Biomarkers

$500K–$1M

With Biomarkers

$1M–$10M+

Up to 10x+

The Difference

Without vs. With Biomarker Evidence

Without Biomarkers

Normal imaging used to deny injury

Symptoms dismissed as subjective

Defense IMEs argue malingering

Lower settlement pressure

Weaker negotiation position

With Biomarkers

Lab-verified neuronal damage on record

Objective data independent of patient narrative

Counters defense challenges at every stage

Justifies higher economic and non-economic damages

Stronger mediation and trial leverage

The Evidence

Core Biomarker Panel

GFAP + UCH-L1

FDA Cleared

Detects glial and neuronal damage within hours. High sensitivity for CT-negative cases.

NfL

Progression Marker

Measures axonal injury and tracks recovery trajectory over time.

Emerging Markers

S100B, p-Tau, miRNA

Next-generation markers for acute detection and long-term prognosis.

Next Steps

Maximize Your Case Value

Obtain Testing

FDA-approved GFAP+UCH-L1 blood draw at approved facilities.

Engage Counsel

TBI-experienced attorneys leverage biomarker evidence in litigation.

Document Damages

Combine results with medical records and expert testimony.

Act Quickly

File within the two-year statute of limitations for strongest evidence.

Ready to Strengthen Your TBI Cases?

Schedule a briefing to learn how biomarker evidence can increase your case outcomes.

Request a Briefing (512) 497-6487